Figures & data
Figure 1 Model structure overview.
![Figure 1 Model structure overview.](/cms/asset/ecae7fad-7a32-41e6-89e1-2417bc2d377e/dceo_a_26621_f0001_b.jpg)
Figure 2 Model cohort simulation.
![Figure 2 Model cohort simulation.](/cms/asset/4935b1b4-1d4c-4b60-bc3b-0999337deae1/dceo_a_26621_f0002_b.jpg)
Table 1 Direct medical cost estimates for cardiovascular events
Table 2 Disutilities for CVD events
Table 3 Base case analysis for cost-effectiveness of rosuvastatin vs generic atorvastatin and simvastatin: lifetime horizon in patients with Framingham risk ≥20% or ≥30%. Results per 1000 patients with 95% generic price reduction assumption
Figure 3 (A) One-way sensitivity analysis of lifetime horizon for Framingham 20% risk population (JUPITER population): rosuvastatin 20 mg versus atorvastatin 40 mg assuming a 95% generic price reduction from brand. (B) One-way sensitivity analysis of lifetime horizon for Framingham 20% risk population (JUPITER population): rosuvastatin 20 mg versus simvastatin 40 mg assuming a 95% generic price reduction from brand.
![Figure 3 (A) One-way sensitivity analysis of lifetime horizon for Framingham 20% risk population (JUPITER population): rosuvastatin 20 mg versus atorvastatin 40 mg assuming a 95% generic price reduction from brand. (B) One-way sensitivity analysis of lifetime horizon for Framingham 20% risk population (JUPITER population): rosuvastatin 20 mg versus simvastatin 40 mg assuming a 95% generic price reduction from brand.](/cms/asset/132352b1-cb2f-4f6a-8946-f1d11032d4fc/dceo_a_26621_f0003_b.jpg)
Table 4 Cost-effectiveness of rosuvastatin (RSV) vs atorvastatin (ATV) and simvastatin (SMV): effect of alteration of time horizon, no future introduction of generic rosuvastatin, and increase in cardiac event relative risk
Figure 4 (A) Willingness to pay-cost/QALY ICER with a lifetime horizon for Framingham 20% risk population (JUPITER population) rosuvastatin 20 mg versus atorvastatin 40 mg, assuming a generic 95% price reduction from brand. (B) Willingness to pay-cost/QALY ICER with a lifetime horizon for Framingham 20% risk population (JUPITER population) rosuvastatin 20 mg versus simvastatin 40 mg, generic 95% price reduction from brand.
![Figure 4 (A) Willingness to pay-cost/QALY ICER with a lifetime horizon for Framingham 20% risk population (JUPITER population) rosuvastatin 20 mg versus atorvastatin 40 mg, assuming a generic 95% price reduction from brand. (B) Willingness to pay-cost/QALY ICER with a lifetime horizon for Framingham 20% risk population (JUPITER population) rosuvastatin 20 mg versus simvastatin 40 mg, generic 95% price reduction from brand.](/cms/asset/2d57cf71-8d2e-418c-9a6c-1667bd93ccee/dceo_a_26621_f0004_b.jpg)